Home>>PSB-KD107

PSB-KD107

Catalog No.GC48004

A GPR18 agonist

Products are for research use only. Not for human use. We do not sell to patients.

PSB-KD107 Chemical Structure

Cas No.: 955121-65-0

Size Price Stock Qty
1 mg
$111.00
In stock
5 mg
$280.00
In stock
10 mg
$502.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

PSB-KD107 is an agonist of the orphan G protein-coupled receptor GPR18 (EC50 = 0.56 µM in a β-arrestin recruitment assay using CHO cells expressing the human receptor).1,2 It is selective for GPR18 over GPR55, as well as cannabinoid (CB) receptor 1 (CB1) and CB2, at 10 µM but also binds to the adenosine A2A receptor (Ki = 0.33 µM for the rat receptor).1,3

1.Schoeder, C.T., Kaleta, M., Mahardhika, A.B., et al.Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18Eur. J. Med. Chem.155381-397(2018) 2.Schoeder, C.T., Mahardhika, A.B., Drabczyńska, A., et al.Discovery of tricyclic xanthines as agonists of the cannabinoid-activated orphan G?protein-coupled receptor GPR18ACS Med. Chem. Lett.(2020) 3.Drabczyńska, A., MÜller, C.E., Schiedel, A., et al.Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: Structure-activity relationships as adenosine A1 and A2A receptor ligandsBioorg. Med. Chem.15(22)6956-6974(2007)

Reviews

Review for PSB-KD107

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PSB-KD107

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.